| Stereochemistry | MIXED |
| Molecular Formula | C20H24N2O5 |
| Molecular Weight | 372.415 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CCC1=CC2=C(OCO2)C=C1)NCC(O)C3=CC(C(N)=O)=C(O)C=C3
InChI
InChIKey=MPQWSYJGFLADEW-UHFFFAOYSA-N
InChI=1S/C20H24N2O5/c1-12(2-3-13-4-7-18-19(8-13)27-11-26-18)22-10-17(24)14-5-6-16(23)15(9-14)20(21)25/h4-9,12,17,22-24H,2-3,10-11H2,1H3,(H2,21,25)
| Molecular Formula | C20H24N2O5 |
| Molecular Weight | 372.415 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Medroxalol is a competitive antagonist at alpha1-adrenergic receptors and beta1-adrenergic receptors. Medroxalol also an agonist at beta2-adrenergic receptors. Medroxalol exerts antihypertensive and vasodilating effects. It was concluded that the principal action of medroxalol was to produce a fall in blood pressure by decreasing peripheral vascular resistance more than cardiac output.
